thymidine has been researched along with HIV Coinfection in 110 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin resistance in PLWH is associated with both use of thymidine analogues and/or didanosine and prior immunodeficiency suggesting that increased attention on blood glucose in these patients could be beneficial." | 8.12 | Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency. ( Benfield, T; Gelpi, M; Gerstoft, J; Hove-Skovsgaard, M; Høgh, J; Jensen, AMR; Nielsen, SD; Storgaard, H, 2022) |
| "To evaluate whether an inter-individual variability in the activity of thymidine kinase (TK) and deoxycytidine kinase (dCK), which are involved in the first step of phosphorylation of some nucleoside analogues, exists in antiretroviral-naive, HIV-seropositive patients." | 7.73 | Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. ( Antonelli, G; Antonelli, L; Butera, O; Gianotti, N; Girardi, E; Iaiani, G; Lazzarin, A; Mazzi, R; Parisi, SG; Turriziani, O, 2005) |
| "To evaluate the prevalence, outcome and possible risk factors for hyperlactataemia and lactic acidosis in HIV-positive persons receiving antiretroviral therapy." | 7.71 | Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. ( Asboe, D; Datta, D; Gazzard, BG; Mandalia, S; Morlese, J; Moyle, GJ, 2002) |
| "Telbivudine is a potent inhibitor of hepatitis B virus (HBV) replication without anti-HIV type-1 (HIV-1) activity demonstrated in vitro; however, very few clinical data on HIV-1-infected patients are available at present." | 5.35 | Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. ( Balotta, C; Caramma, I; Cesari, M; De Maddalena, C; Galli, M; Lai, A; Milazzo, L; Violin, M, 2009) |
| " Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1." | 4.87 | Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011) |
| "Insulin resistance in PLWH is associated with both use of thymidine analogues and/or didanosine and prior immunodeficiency suggesting that increased attention on blood glucose in these patients could be beneficial." | 4.12 | Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency. ( Benfield, T; Gelpi, M; Gerstoft, J; Hove-Skovsgaard, M; Høgh, J; Jensen, AMR; Nielsen, SD; Storgaard, H, 2022) |
| "To evaluate whether an inter-individual variability in the activity of thymidine kinase (TK) and deoxycytidine kinase (dCK), which are involved in the first step of phosphorylation of some nucleoside analogues, exists in antiretroviral-naive, HIV-seropositive patients." | 3.73 | Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. ( Antonelli, G; Antonelli, L; Butera, O; Gianotti, N; Girardi, E; Iaiani, G; Lazzarin, A; Mazzi, R; Parisi, SG; Turriziani, O, 2005) |
| "To evaluate the prevalence, outcome and possible risk factors for hyperlactataemia and lactic acidosis in HIV-positive persons receiving antiretroviral therapy." | 3.71 | Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. ( Asboe, D; Datta, D; Gazzard, BG; Mandalia, S; Morlese, J; Moyle, GJ, 2002) |
| " The primary endpoints were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL and safety events (serious adverse events and adverse events leading to discontinuation) through week 24; the main analysis was with a modified intention-to-treat population." | 2.82 | Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. ( Avihingsanon, A; Echevarría, J; Gupta, SK; Hanna, GJ; Joshi, SR; Lataillade, M; Lombaard, J; McComsey, GA; Orrell, C; Osiyemi, O; Ray, N; Santoscoy, M; Stock, DA, 2016) |
| "BMS-986001 was generally well tolerated, with no discontinuations due to adverse events and no deaths occurring." | 2.78 | Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects. ( Bertz, R; Boué, F; Chan, HP; Chang, I; Cotte, L; Dellamonica, P; Grasela, DM; Hanna, GJ; Hwang, C; Molina, JM; Raffi, F; Urata, Y; Yazdanpanah, Y; Zhu, L, 2013) |
| "To compare the safety and efficacy of stavudine (d4T) + lamivudine (3TC) with zidovudine (ZDV) + 3TC, each in combination with indinavir (IDV)." | 2.69 | A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). ( Clark, R; Cohen, C; Cooley, T; Grosso, R; Gulick, R; Marlowe, SI; Mauney, J; Mulanovich, V; Santana, J; Schoellkopf, N; Squires, KE; Stevens, M; Tebas, P; Uffelman, K; Wright, D; Yangco, B, 2000) |
| "In patients not requiring HAART, treatment of hepatitis B should preferably consist of drugs without activity against HIV, such as pegylated interferon or adefovir." | 2.44 | [Hepatitis B in patients with HIV infection]. ( Barreiro, P; García-Samaniego, J; Martín-Carbonero, L, 2008) |
| "The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy." | 2.44 | [Tenofovir as a strategy to avoid or limit adverse effects]. ( Portilla, J, 2008) |
| "1." | 2.39 | [In vitro synergic lymphocyte stimulation in HIV-1 infected patients using inosine derivatives and radio-detoxified endotoxin]. ( Bertók, L; Friedman, H; Hadden, JW; Nelson, R; Ongrádi, J; Specter, S, 1995) |
| "Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV." | 1.39 | In vivo antiviral activity of telbivudine against HIV-1: a case report. ( Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013) |
| "Chronic hepatitis B affects 5-10% of HIV patients in Western countries." | 1.35 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009) |
| "Telbivudine is a potent inhibitor of hepatitis B virus (HBV) replication without anti-HIV type-1 (HIV-1) activity demonstrated in vitro; however, very few clinical data on HIV-1-infected patients are available at present." | 1.35 | Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. ( Balotta, C; Caramma, I; Cesari, M; De Maddalena, C; Galli, M; Lai, A; Milazzo, L; Violin, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (4.55) | 18.2507 |
| 2000's | 65 (59.09) | 29.6817 |
| 2010's | 37 (33.64) | 24.3611 |
| 2020's | 3 (2.73) | 2.80 |
| Authors | Studies |
|---|---|
| Høgh, J | 1 |
| Hove-Skovsgaard, M | 1 |
| Gelpi, M | 3 |
| Jensen, AMR | 1 |
| Gerstoft, J | 2 |
| Benfield, T | 1 |
| Storgaard, H | 1 |
| Nielsen, SD | 3 |
| Hunt, M | 1 |
| Phillips, R | 1 |
| Hardy, Y | 1 |
| Owusu, DO | 1 |
| Mitchelmore, R | 1 |
| Durrani, M | 1 |
| Payne, BAI | 1 |
| Chadwick, DR | 1 |
| Knudsen, AD | 2 |
| Larsen, KB | 1 |
| Mocroft, A | 3 |
| Lebech, AM | 2 |
| Lindegaard, B | 2 |
| Lundgren, J | 2 |
| Kofoed, KF | 2 |
| Miti, S | 1 |
| Handema, R | 1 |
| Mulenga, L | 1 |
| Mwansa, JK | 1 |
| Abrams, E | 1 |
| Frimpong, C | 1 |
| Burke, VM | 1 |
| Zulu, M | 1 |
| Siwingwa, M | 1 |
| Mwakazanga, D | 1 |
| Kalibala, S | 1 |
| Denison, JA | 1 |
| Margot, NA | 2 |
| Wong, P | 1 |
| Kulkarni, R | 1 |
| White, K | 1 |
| Porter, D | 1 |
| Abram, ME | 1 |
| Callebaut, C | 1 |
| Miller, MD | 3 |
| Karade, SK | 1 |
| Kulkarni, SS | 1 |
| Ghate, MV | 1 |
| Patil, AA | 1 |
| Londhe, R | 1 |
| Salvi, SP | 1 |
| Kadam, DB | 1 |
| Joshi, RK | 1 |
| Rewari, BB | 1 |
| Gangakhedkar, RR | 1 |
| Virgilio, A | 1 |
| Amato, T | 1 |
| Petraccone, L | 1 |
| Esposito, F | 1 |
| Grandi, N | 1 |
| Tramontano, E | 1 |
| Romero, R | 1 |
| Haider, S | 1 |
| Gomez-Monterrey, I | 1 |
| Novellino, E | 1 |
| Mayol, L | 1 |
| Esposito, V | 1 |
| Galeone, A | 1 |
| Afzal, S | 1 |
| Fuchs, A | 1 |
| Drivsholm, N | 1 |
| Kühl, JT | 1 |
| Sigvardsen, PE | 1 |
| Køber, L | 1 |
| Nordestgaard, BG | 1 |
| Sigaloff, KC | 2 |
| Kayiwa, J | 1 |
| Musiime, V | 1 |
| Calis, JC | 1 |
| Kaudha, E | 1 |
| Mukuye, A | 1 |
| Matama, C | 1 |
| Nankya, I | 2 |
| Nakatudde, L | 1 |
| Dekker, JT | 1 |
| Hamers, RL | 2 |
| Mugyenyi, P | 2 |
| Rinke De Wit, TF | 1 |
| Kityo, C | 4 |
| Santoro, MM | 1 |
| Sabin, C | 1 |
| Forbici, F | 1 |
| Bansi, L | 1 |
| Dunn, D | 1 |
| Fearnhill, E | 1 |
| Boumis, E | 1 |
| Nicastri, E | 1 |
| Antinori, A | 3 |
| Palamara, G | 1 |
| Callegaro, A | 1 |
| Francisci, D | 2 |
| Zoncada, A | 1 |
| Maggiolo, F | 3 |
| Zazzi, M | 2 |
| Perno, CF | 5 |
| Ceccherini-Silberstein, F | 3 |
| Mussini, C | 2 |
| Invernizzi, CF | 1 |
| Coutsinos, D | 1 |
| Oliveira, M | 1 |
| Schildknecht, RS | 1 |
| Xu, H | 1 |
| Gaseitsiwe, S | 2 |
| Moisi, D | 1 |
| Brenner, BG | 1 |
| Wainberg, MA | 1 |
| Cotte, L | 1 |
| Dellamonica, P | 1 |
| Raffi, F | 1 |
| Yazdanpanah, Y | 2 |
| Molina, JM | 1 |
| Boué, F | 1 |
| Urata, Y | 1 |
| Chan, HP | 1 |
| Zhu, L | 1 |
| Chang, I | 1 |
| Bertz, R | 1 |
| Hanna, GJ | 3 |
| Grasela, DM | 1 |
| Hwang, C | 2 |
| Messou, E | 1 |
| Chaix, ML | 1 |
| Gabillard, D | 1 |
| Yapo, V | 1 |
| Toni, TD | 1 |
| Minga, A | 1 |
| Kouakou, MG | 1 |
| Ouattara, E | 1 |
| Rouzioux, C | 1 |
| Danel, C | 1 |
| Eholie, SP | 1 |
| Anglaret, X | 1 |
| Li, Z | 1 |
| Terry, B | 1 |
| Olds, W | 1 |
| Protack, T | 1 |
| Deminie, C | 1 |
| Minassian, B | 1 |
| Nowicka-Sans, B | 1 |
| Sun, Y | 1 |
| Dicker, I | 1 |
| Lataillade, M | 2 |
| Krystal, M | 1 |
| Gentile, I | 1 |
| Bonadies, G | 1 |
| Carleo, MA | 1 |
| Buonomo, AR | 1 |
| Borrelli, F | 1 |
| Portella, G | 1 |
| Borgia, G | 1 |
| Maeda, K | 1 |
| Desai, DV | 1 |
| Aoki, M | 1 |
| Nakata, H | 1 |
| Kodama, EN | 1 |
| Mitsuya, H | 1 |
| Gupta, SK | 1 |
| McComsey, GA | 2 |
| Lombaard, J | 1 |
| Echevarría, J | 1 |
| Orrell, C | 1 |
| Avihingsanon, A | 1 |
| Osiyemi, O | 1 |
| Santoscoy, M | 1 |
| Ray, N | 1 |
| Stock, DA | 1 |
| Joshi, SR | 1 |
| Goodall, RL | 1 |
| Dunn, DT | 1 |
| Nkurunziza, P | 1 |
| Mugarura, L | 1 |
| Pattery, T | 1 |
| Munderi, P | 1 |
| Gilks, C | 1 |
| Kaleebu, P | 1 |
| Pillay, D | 1 |
| Gupta, RK | 1 |
| Charpentier, C | 1 |
| Laureillard, D | 1 |
| Sodqi, M | 1 |
| Si-Mohamed, A | 1 |
| Karmochkine, M | 1 |
| Bélec, L | 1 |
| Weiss, L | 1 |
| Piketty, C | 1 |
| Barreiro, P | 2 |
| Martín-Carbonero, L | 2 |
| García-Samaniego, J | 1 |
| Portilla, J | 1 |
| López Bernaldo de Quirós, JC | 1 |
| Miralles Alvarez, C | 1 |
| Low, E | 1 |
| Cox, A | 1 |
| Atkins, M | 1 |
| Nelson, M | 2 |
| Oyugi, JO | 1 |
| Vouriot, FC | 1 |
| Alimonti, J | 1 |
| Wayne, S | 1 |
| Luo, M | 1 |
| Land, AM | 1 |
| Ao, Z | 1 |
| Yao, X | 1 |
| Sekaly, RP | 1 |
| Elliott, LJ | 1 |
| Simonsen, JN | 1 |
| Ball, TB | 1 |
| Jaoko, W | 1 |
| Kimani, J | 1 |
| Plummer, FA | 1 |
| Fowke, KR | 1 |
| Ribera Pascuet, E | 1 |
| Curran, A | 1 |
| Reynolds, SJ | 1 |
| Mbamanya, F | 1 |
| Dewar, R | 1 |
| Ssali, F | 1 |
| Quinn, TC | 1 |
| Dybul, M | 1 |
| Zaunders, JJ | 1 |
| Munier, ML | 1 |
| Seddiki, N | 1 |
| Pett, S | 1 |
| Ip, S | 1 |
| Bailey, M | 1 |
| Xu, Y | 1 |
| Brown, K | 1 |
| Dyer, WB | 1 |
| Kim, M | 1 |
| de Rose, R | 1 |
| Kent, SJ | 1 |
| Jiang, L | 1 |
| Breit, SN | 1 |
| Emery, S | 2 |
| Cunningham, AL | 1 |
| Cooper, DA | 2 |
| Kelleher, AD | 2 |
| Galegov, GA | 2 |
| Soriano, V | 3 |
| Tuma, P | 1 |
| Vispo, E | 1 |
| Labarga, P | 1 |
| Fernández, JV | 1 |
| Medrano, J | 1 |
| Calza, L | 1 |
| Manfredi, R | 1 |
| Colangeli, V | 1 |
| Pocaterra, D | 1 |
| Rosseti, N | 1 |
| Pavoni, M | 1 |
| Chiodo, F | 2 |
| Milazzo, L | 1 |
| Caramma, I | 1 |
| Lai, A | 2 |
| Violin, M | 3 |
| De Maddalena, C | 1 |
| Cesari, M | 1 |
| Galli, M | 3 |
| Balotta, C | 3 |
| Gottardi, M | 1 |
| Lanzafame, M | 1 |
| Lattuada, E | 1 |
| Soldani, F | 1 |
| Boccafoglio, F | 1 |
| Concia, E | 1 |
| Riedel, DJ | 1 |
| Amoroso, A | 1 |
| Radzio, J | 1 |
| Yap, SH | 1 |
| Tachedjian, G | 1 |
| Sluis-Cremer, N | 2 |
| Lin, K | 1 |
| Karwowska, S | 1 |
| Lam, E | 1 |
| Limoli, K | 1 |
| Evans, TG | 1 |
| Avila, C | 1 |
| Tungsiripat, M | 1 |
| Bejjani, DE | 1 |
| Rizk, N | 1 |
| O'riordan, MA | 1 |
| Ross, AC | 1 |
| Hileman, C | 1 |
| Storer, N | 1 |
| Harrill, D | 1 |
| Zou, W | 1 |
| Wang, Z | 1 |
| Liu, Y | 1 |
| Fan, Y | 1 |
| Zhou, BY | 1 |
| Yang, XF | 1 |
| He, JJ | 1 |
| Neogi, U | 1 |
| Prarthana, BS | 1 |
| Gupta, S | 1 |
| D'souza, G | 1 |
| De Costa, A | 1 |
| Kuttiatt, VS | 1 |
| Arumugam, K | 1 |
| Shet, A | 1 |
| Pais, R | 1 |
| Benhamou, Y | 1 |
| Mallet, V | 1 |
| Vallet-Pichard, A | 1 |
| Pol, S | 1 |
| Ortiz, M | 1 |
| Poloni, ES | 1 |
| Furrer, H | 1 |
| Kovari, H | 1 |
| Martinez, R | 1 |
| Arnedo, M | 1 |
| Elzi, L | 1 |
| Bernasconi, E | 1 |
| Vernazza, P | 1 |
| Hirschel, B | 1 |
| Cavassini, M | 1 |
| Ledergerber, B | 3 |
| Günthard, HF | 3 |
| Telenti, A | 1 |
| Tarr, PE | 1 |
| Lengruber, RB | 1 |
| Delviks-Frankenberry, KA | 1 |
| Nikolenko, GN | 1 |
| Baumann, J | 1 |
| Santos, AF | 1 |
| Pathak, VK | 1 |
| Soares, MA | 1 |
| Gaynor, JW | 1 |
| Cosstick, R | 1 |
| Wallis, CL | 1 |
| Siwale, M | 1 |
| Mandaliya, K | 1 |
| Conradie, F | 1 |
| Botes, ME | 1 |
| Wellington, M | 1 |
| Osibogun, A | 1 |
| Schuurman, R | 1 |
| Wit, FW | 1 |
| Stevens, WS | 1 |
| van Vugt, M | 1 |
| de Wit, TF | 1 |
| Moura, M | 1 |
| Josse, S | 1 |
| Nguyen Van Nhien, A | 1 |
| Fournier, C | 1 |
| Duverlie, G | 1 |
| Castelain, S | 1 |
| Soriano, E | 1 |
| Marco-Contelles, J | 1 |
| Balzarini, J | 4 |
| Postel, D | 1 |
| Ebranati, E | 1 |
| Franzetti, M | 1 |
| Micheli, V | 1 |
| Gismondo, MR | 1 |
| Capetti, A | 1 |
| Meraviglia, P | 1 |
| Simonetti, FR | 1 |
| Bozzi, G | 1 |
| Ciccozzi, M | 1 |
| Zehender, G | 1 |
| Razonable, RR | 1 |
| van Maarseveen, NM | 1 |
| Wensing, AM | 1 |
| de Jong, D | 1 |
| Beilhartz, GL | 1 |
| Obikhod, A | 1 |
| Tao, S | 1 |
| Pingen, M | 1 |
| Arends, JE | 1 |
| Hoepelman, AI | 1 |
| Schinazi, RF | 1 |
| Götte, M | 3 |
| Nijhuis, M | 1 |
| Scherrer, AU | 1 |
| von Wyl, V | 1 |
| Klimkait, T | 1 |
| Cellerai, C | 1 |
| Yerly, S | 1 |
| Böni, J | 1 |
| Held, L | 1 |
| Fourati, S | 1 |
| Malet, I | 2 |
| Guenzel, CA | 1 |
| Soulie, C | 1 |
| Maidou-Peindara, P | 1 |
| Morand-Joubert, L | 1 |
| Wirden, M | 3 |
| Sayon, S | 1 |
| Peytavin, G | 1 |
| Simon, A | 3 |
| Katlama, C | 4 |
| Benichou, S | 1 |
| Calvez, V | 3 |
| Marcelin, AG | 3 |
| Saravanan, S | 1 |
| Madhavan, V | 1 |
| Solomon, SS | 1 |
| Kantor, R | 1 |
| Katzenstein, D | 1 |
| Sivamalar, S | 1 |
| Kumarasamy, N | 1 |
| Smith, DM | 1 |
| Mayer, KH | 1 |
| Solomon, S | 1 |
| Balakrishnan, P | 1 |
| Melikian, GL | 1 |
| Rhee, SY | 1 |
| Taylor, J | 1 |
| Fessel, WJ | 1 |
| Kaufman, D | 1 |
| Towner, W | 1 |
| Troia-Cancio, PV | 1 |
| Zolopa, A | 1 |
| Robbins, GK | 1 |
| Kagan, R | 1 |
| Israelski, D | 1 |
| Shafer, RW | 2 |
| Stankov, MV | 1 |
| Panayotova-Dimitrova, D | 1 |
| Leverkus, M | 1 |
| Vondran, FW | 1 |
| Bauerfeind, R | 1 |
| Binz, A | 1 |
| Behrens, GM | 1 |
| Cordery, DV | 1 |
| Martin, A | 1 |
| Amin, J | 1 |
| Praparattanapan, J | 1 |
| Kotarathitithum, W | 1 |
| Chaiwarith, R | 1 |
| Nuntachit, N | 1 |
| Sirisanthana, T | 1 |
| Supparatpinyo, K | 1 |
| Moyle, GJ | 2 |
| Datta, D | 1 |
| Mandalia, S | 2 |
| Morlese, J | 1 |
| Asboe, D | 1 |
| Gazzard, BG | 2 |
| Ait-Khaled, M | 1 |
| Stone, C | 1 |
| Amphlett, G | 1 |
| Clotet, B | 5 |
| Staszewski, S | 3 |
| Tisdale, M | 2 |
| Uckun, FM | 1 |
| Pendergrass, S | 1 |
| Venkatachalam, TK | 1 |
| Qazi, S | 1 |
| Richman, D | 1 |
| Shulman, NS | 1 |
| Hughes, MD | 1 |
| Winters, MA | 1 |
| Zolopa, AR | 1 |
| Hellmann, NS | 1 |
| Bates, M | 2 |
| Whitcomb, JM | 1 |
| Katzenstein, DA | 1 |
| Flandre, P | 1 |
| Descamps, D | 1 |
| Joly, V | 1 |
| Meiffrédy, V | 1 |
| Tamalet, C | 1 |
| Izopet, J | 1 |
| Aboulker, JP | 1 |
| Brun-Vézinet, F | 1 |
| Delaugerre, C | 1 |
| Viegas, P | 1 |
| Bocket, L | 1 |
| Ajana, F | 1 |
| Gerard, Y | 1 |
| Viget, N | 1 |
| Goffard, A | 1 |
| Alcaraz, I | 1 |
| Wattré, P | 1 |
| Mouton, Y | 1 |
| Margot, N | 1 |
| Lu, B | 1 |
| Zhong, L | 1 |
| Chen, SS | 1 |
| Cheng, A | 1 |
| Wulfsohn, M | 1 |
| White, KL | 1 |
| Chen, JM | 1 |
| Wrin, T | 1 |
| Petropoulos, CJ | 1 |
| Naeger, LK | 1 |
| Swaminathan, S | 1 |
| Cozzi-Lepri, A | 3 |
| Velleca, R | 1 |
| Vincenti, A | 1 |
| D'Elia, S | 1 |
| Ghinelli, F | 1 |
| Bertoli, A | 1 |
| d'Arminio Monforte, A | 1 |
| Moroni, M | 1 |
| Haraguchi, K | 1 |
| Itoh, Y | 1 |
| Takeda, S | 1 |
| Honma, Y | 1 |
| Tanaka, H | 1 |
| Nitanda, T | 1 |
| Baba, M | 1 |
| Dutschman, GE | 1 |
| Cheng, YC | 1 |
| Ross, L | 2 |
| Parkin, N | 1 |
| Chappey, C | 1 |
| Fisher, R | 2 |
| Clair, MS | 1 |
| Lanier, ER | 2 |
| Valer, L | 1 |
| de Mendoza, C | 1 |
| Corral, A | 1 |
| Turriziani, O | 2 |
| Butera, O | 1 |
| Gianotti, N | 2 |
| Parisi, SG | 1 |
| Mazzi, R | 1 |
| Girardi, E | 1 |
| Iaiani, G | 1 |
| Antonelli, L | 1 |
| Lazzarin, A | 1 |
| Antonelli, G | 2 |
| Derache, A | 1 |
| Roquebert, B | 1 |
| Kirstetter, M | 1 |
| Joubert, LM | 1 |
| García-Lerma, JG | 1 |
| Miranda, LR | 1 |
| Liang, F | 1 |
| Kuritzkes, DR | 1 |
| Lo Cicero, M | 1 |
| Bulgheroni, E | 1 |
| Soster, F | 1 |
| Viganò, O | 1 |
| Cicconi, P | 1 |
| Rusconi, S | 1 |
| Sutthent, R | 1 |
| Arworn, D | 1 |
| Kaoriangudom, S | 1 |
| Chokphaibulkit, K | 1 |
| Chaisilwatana, P | 1 |
| Wirachsilp, P | 1 |
| Thiamchai, V | 1 |
| Sirapraphasiri, T | 1 |
| Tanprasertsuk, S | 1 |
| Ruiz, L | 3 |
| Loveday, C | 1 |
| Phillips, AN | 2 |
| Reiss, P | 2 |
| Holkmann, C | 1 |
| Lundgren, JD | 2 |
| Waters, LJ | 1 |
| Nelson, MR | 1 |
| Mauss, S | 1 |
| Borderi, M | 1 |
| De Luca, A | 2 |
| Di Giambenedetto, S | 1 |
| Romano, L | 1 |
| Gonnelli, A | 1 |
| Corsi, P | 1 |
| Baldari, M | 1 |
| Di Pietro, M | 1 |
| Menzo, S | 1 |
| Almi, P | 1 |
| de Castro, S | 1 |
| García-Aparicio, C | 1 |
| Van Laethem, K | 2 |
| Gago, F | 1 |
| Lobatón, E | 1 |
| De Clercq, E | 2 |
| Camarasa, MJ | 2 |
| Velázquez, S | 1 |
| Blanco, JL | 1 |
| Biglia, A | 1 |
| De Lazzari, E | 1 |
| Mallolas, J | 1 |
| Martinez, E | 1 |
| Pumarola, T | 1 |
| Larrousse, M | 1 |
| Milinkovic, A | 1 |
| León, A | 1 |
| Lonca, M | 1 |
| Laguno, M | 1 |
| Gatell, JM | 2 |
| Averbuch, D | 1 |
| Schapiro, JM | 1 |
| Gradstein, S | 1 |
| Gottesman, G | 1 |
| Kedem, E | 1 |
| Einhorn, M | 1 |
| Grisaru-Soen, G | 1 |
| Ofir, M | 1 |
| Engelhard, D | 1 |
| Grossman, Z | 1 |
| de Medeiros, LB | 1 |
| Lacerda, HR | 1 |
| Cavalcanti, AM | 1 |
| de Albuquerque, Mde F | 1 |
| Ripamonti, D | 1 |
| Torti, C | 2 |
| Arici, C | 1 |
| Quiros-Roldan, E | 1 |
| Minoli, L | 1 |
| Sighinolfi, L | 1 |
| Nasta, P | 1 |
| Suter, F | 1 |
| Stürmer, M | 1 |
| Dauer, B | 1 |
| Moesch, M | 1 |
| Haberl, A | 1 |
| Mueller, A | 1 |
| Locher, L | 1 |
| Knecht, G | 1 |
| Hanke, N | 1 |
| Doerr, HW | 2 |
| Parikh, UM | 1 |
| Zelina, S | 1 |
| Mellors, JW | 1 |
| Garcia-Gasco, P | 1 |
| Sheldon, J | 1 |
| Mathiesen, S | 1 |
| Dam, E | 1 |
| Roge, B | 1 |
| Joergensen, LB | 1 |
| Laursen, AL | 1 |
| Clavel, F | 1 |
| Novitsky, V | 1 |
| Wester, CW | 1 |
| DeGruttola, V | 1 |
| Bussmann, H | 1 |
| Thomas, A | 1 |
| Moyo, S | 1 |
| Musonda, R | 1 |
| Van Widenfelt, E | 1 |
| Marlink, RG | 1 |
| Essex, M | 1 |
| Olsen, CH | 1 |
| Trotta, MP | 1 |
| Lorenzini, P | 1 |
| Nasto, P | 1 |
| Castagna, A | 1 |
| Andreoni, M | 1 |
| Peng, H | 1 |
| Whitney, N | 1 |
| Wu, Y | 1 |
| Tian, C | 1 |
| Dou, H | 1 |
| Zhou, Y | 1 |
| Zheng, J | 1 |
| Caron, M | 1 |
| Auclairt, M | 1 |
| Vissian, A | 1 |
| Vigouroux, C | 1 |
| Capeau, J | 1 |
| Llibre, JM | 1 |
| Bonjoch, A | 1 |
| Iribarren, J | 1 |
| Galindo, MJ | 1 |
| Negredo, E | 1 |
| Domingo, P | 1 |
| Pérez-Alvarez, N | 1 |
| Martinez-Picado, J | 1 |
| Schapiro, J | 1 |
| Ongrádi, J | 1 |
| Hadden, JW | 1 |
| Bertók, L | 1 |
| Specter, S | 1 |
| Nelson, R | 1 |
| Friedman, H | 1 |
| Krowka, JF | 1 |
| Cuevas, B | 1 |
| Maron, DC | 1 |
| Steimer, KS | 1 |
| Ascher, MS | 1 |
| Sheppard, HW | 1 |
| Verri, A | 1 |
| Narciso, P | 1 |
| Ferri, F | 1 |
| D'Offizi, G | 1 |
| Dianzani, F | 1 |
| Schmit, JC | 1 |
| Pelemans, H | 1 |
| Witvrouw, M | 1 |
| Pérez-Pérez, MJ | 1 |
| Esnouf, RM | 1 |
| Aquaro, S | 1 |
| Cenci, A | 1 |
| Hermans, P | 1 |
| Sprecher, S | 1 |
| Van Wijngaerden, E | 1 |
| Van Ranst, M | 1 |
| Desmyter, J | 1 |
| Vandamme, AM | 1 |
| Squires, KE | 1 |
| Gulick, R | 1 |
| Tebas, P | 1 |
| Santana, J | 1 |
| Mulanovich, V | 1 |
| Clark, R | 1 |
| Yangco, B | 1 |
| Marlowe, SI | 1 |
| Wright, D | 1 |
| Cohen, C | 1 |
| Cooley, T | 1 |
| Mauney, J | 1 |
| Uffelman, K | 1 |
| Schoellkopf, N | 2 |
| Grosso, R | 2 |
| Stevens, M | 2 |
| Eron, JJ | 1 |
| Murphy, RL | 1 |
| Peterson, D | 1 |
| Pottage, J | 1 |
| Parenti, DM | 1 |
| Jemsek, J | 1 |
| Swindells, S | 1 |
| Sepulveda, G | 1 |
| Bellos, N | 1 |
| Rashbaum, BC | 1 |
| Esinhart, J | 1 |
| Matthews, GV | 1 |
| Bower, M | 1 |
| Becker, SL | 1 |
| Raffanti, SR | 1 |
| Hansen, NI | 1 |
| Fusco, JS | 1 |
| Fusco, GP | 1 |
| Slatko, GH | 1 |
| Igboko, EF | 1 |
| Graham, NM | 1 |
| Scarsella, A | 1 |
| Raffanti, S | 1 |
| Henry, K | 1 |
| Becker, S | 1 |
| Liao, Q | 1 |
| Hirani, A | 1 |
| Graham, N | 1 |
| St Clair, M | 1 |
| Hernandez, J | 1 |
| Toomey, NL | 1 |
| Deyev, VV | 1 |
| Wood, C | 1 |
| Boise, LH | 1 |
| Scott, D | 1 |
| Liu, LH | 1 |
| Cabral, L | 1 |
| Podack, ER | 1 |
| Barber, GN | 1 |
| Harrington, WJ | 1 |
| Gröschel, B | 1 |
| Cinatl, J | 2 |
| Périgaud, C | 1 |
| Gosselin, G | 1 |
| Imbach, JL | 1 |
| Suzuki, J | 1 |
| Miyano-Kurosaki, N | 1 |
| Kuwasaki, T | 1 |
| Takeuchi, H | 1 |
| Kawai, G | 1 |
| Takaku, H | 1 |
| Kitano, K | 1 |
| Baldwin, GC | 1 |
| Raines, MA | 1 |
| Golde, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose[NCT01489046] | Phase 2 | 297 participants (Actual) | Interventional | 2011-02-28 | Terminated | ||
| Nickel Desensitization Using Topical Therapy[NCT01413477] | 24 participants (Anticipated) | Interventional | 2011-08-31 | Not yet recruiting | |||
| Placebo Controlled Study of Rosiglitazone in HIV Lipoatrophy[NCT00367744] | Phase 2 | 71 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy[NCT00000831] | Phase 2 | 280 participants | Interventional | Completed | |||
| EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV[NCT02699736] | 23,000 participants (Actual) | Observational [Patient Registry] | 1994-01-31 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Limb fat was measured at baseline and visit week 48 using dual-energy x-ray absorptiometry (DEXA), and change from baseline to week 48 (week 48 - baseline) was estimated for the treatment groups. (NCT00367744)
Timeframe: 48 weeks
| Intervention | grams (Median) |
|---|---|
| Rosiglitazone | 448 |
| Placebo | 153 |
Carotid IMT of the Common carotid artery (CCA) was measured at baseline and week 48, and change from baseline to week 48 (week 48 - baseline) was estimated for the treatment groups. (NCT00367744)
Timeframe: 48 weeks
| Intervention | mm (Median) |
|---|---|
| Rosiglitazone | 0.10 |
| Placebo | 0.15 |
14 reviews available for thymidine and HIV Coinfection
| Article | Year |
|---|---|
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deox | 2008 |
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Dou | 2008 |
[Tenofovir DF in rescue regimens].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Clinical Trials, Phase III as Topic; Drug Resistance, Mul | 2008 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Dis | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug | 2008 |
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, | 2009 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitab | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; | 2011 |
[Nikavir (phosphazide)--an antiretroviral agent: anti-HIV activity, toxicology, pharmacokinetics and some perspectives of its clinical use].
Topics: Administration, Oral; Animals; Anti-Retroviral Agents; Azides; Capsules; Cell Line; Clinical Trials | 2004 |
Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV- | 2005 |
Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
Topics: Antiretroviral Therapy, Highly Active; Drug Combinations; HIV Infections; HIV Protease Inhibitors; H | 2005 |
[Use of thymidine-sparing regimens in first-line therapy and in switches from thymidine analogues].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Stavudine; Thymidine | 2005 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; | 2007 |
[In vitro synergic lymphocyte stimulation in HIV-1 infected patients using inosine derivatives and radio-detoxified endotoxin].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Endotoxins; HIV Infections; HIV-1; | 1995 |
12 trials available for thymidine and HIV Coinfection
| Article | Year |
|---|---|
Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Adm | 2013 |
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
Topics: Adolescent; Adult; Bone and Bones; Bone Density; Female; HIV Infections; HIV-1; Humans; Male; Middle | 2016 |
Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; HIV Infecti | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycy | 2009 |
Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Cholesterol; Double-Blind Method; Female; HIV Infecti | 2010 |
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitiv | 2002 |
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; | 2003 |
Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Coun | 2004 |
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Met | 2004 |
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow-Up Stud | 2000 |
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Did | 2000 |
Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug T | 2001 |
84 other studies available for thymidine and HIV Coinfection
| Article | Year |
|---|---|
Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency.
Topics: Diabetes Mellitus, Type 2; Didanosine; Female; HIV Infections; Humans; Insulin Resistance; Male; Mid | 2022 |
Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people with HIV.
Topics: Anti-HIV Agents; Ghana; HIV Infections; Humans; Mitochondria; Renal Insufficiency; Tenofovir; Thymid | 2022 |
Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure.
Topics: Adiponectin; Adipose Tissue; Adult; Anti-HIV Agents; Biomarkers; Cross-Sectional Studies; Didanosine | 2019 |
Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Topics: Adolescent; Anti-HIV Agents; Clinical Decision-Making; Cross-Sectional Studies; Drug Resistance, Vir | 2020 |
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV | 2017 |
Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cro | 2017 |
Improvement of the activity of the anti-HIV-1 integrase aptamer T30175 by introducing a modified thymidine into the loops.
Topics: Aptamers, Nucleotide; Drug Discovery; G-Quadruplexes; HIV Infections; HIV Integrase; HIV Integrase I | 2018 |
Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors.
Topics: Adipose Tissue; Adult; Aged; Anti-HIV Agents; Cardiovascular Diseases; Denmark; Didanosine; Female; | 2019 |
Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
Topics: Amino Acid Substitution; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Res | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxyc | 2013 |
The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutatio | 2013 |
Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cote d'Ivoire; Drug Monitoring; Drug Resistance, Viral; Fema | 2013 |
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Topics: Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbia | 2013 |
In vivo antiviral activity of telbivudine against HIV-1: a case report.
Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B | 2013 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Mult | 2014 |
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymph | 2017 |
Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Foscarnet; HIV In | 2008 |
Telbivudine has activity against HIV-1.
Topics: Anti-HIV Agents; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides | 2009 |
A common CD4 gene variant is associated with an increased risk of HIV-1 infection in Kenyan female commercial sex workers.
Topics: Acquired Immunodeficiency Syndrome; CD4 Antigens; Cytidine; DNA Primers; Female; Genetic Predisposit | 2009 |
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R | 2009 |
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40).
Topics: Adult; Amino Acid Sequence; Animals; CD4-Positive T-Lymphocytes; Cells, Cultured; Chronic Disease; E | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan | 2009 |
Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; | 2009 |
Perspectives on treatment failure with thymidine analogue-based first-line regimens in resource-limited settings.
Topics: Drug Resistance, Viral; Health Resources; HIV Infections; HIV Reverse Transcriptase; Humans; Mutatio | 2009 |
N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
Topics: Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation | 2010 |
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, | 2010 |
Involvement of p300 in constitutive and HIV-1 Tat-activated expression of glial fibrillary acidic protein in astrocytes.
Topics: Astrocytes; beta-Galactosidase; Cell Line, Tumor; Cell Proliferation; E1A-Associated p300 Protein; E | 2010 |
Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Multiple, Viral; Evol | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Vi | 2010 |
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.
Topics: Adult; Anti-Retroviral Agents; Case-Control Studies; Cohort Studies; DNA, Mitochondrial; Haplotypes; | 2011 |
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
Topics: Amino Acid Substitution; Anti-HIV Agents; Brazil; Drug Resistance, Viral; HIV Infections; HIV Revers | 2011 |
Dinucleotides containing 3'-S-phosphorothiolate linkages.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dinucleoside Phosphates; Endonucleases; Hepatitis B; He | 2011 |
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
Topics: Adult; Africa South of the Sahara; Aged; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agen | 2011 |
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
Topics: Cell Line; Chemistry Techniques, Synthetic; Hepacivirus; Hepatitis C; HIV Infections; HIV Reverse Tr | 2011 |
Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals.
Topics: Adult; Aged; Anti-HIV Agents; Bayes Theorem; Drug Resistance, Viral; Female; HIV Infections; HIV-1; | 2012 |
Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cell Line; Coinfection; DNA, Viral; Drug Resistance, | 2011 |
Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M.
Topics: Amino Acid Substitution; Anti-HIV Agents; Cohort Studies; Drug Resistance, Multiple, Viral; Gene Fre | 2012 |
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.
Topics: Adult; Aged; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; Genes, vpr; HEK293 Cells; | 2012 |
Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations.
Topics: Amino Acid Substitution; Codon; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; HIV Inf | 2012 |
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
Topics: Adenine; Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genomics | 2012 |
Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation.
Topics: Anti-HIV Agents; Autophagy; Blotting, Western; Cells, Cultured; DNA, Mitochondrial; Fatty Liver; Fem | 2012 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyt | 2012 |
Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Drug Resistance, Multiple, Viral; Female; HIV Infectio | 2012 |
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; F | 2002 |
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
Topics: Drug Resistance, Microbial; Genotype; HIV Infections; HIV-1; Humans; Mutation; Phenotype; Retrospect | 2002 |
Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations.
Topics: Anti-HIV Agents; Dideoxynucleotides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcripta | 2002 |
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; H | 2004 |
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
Topics: Adenine; Adenosine Triphosphate; Cells, Cultured; DNA Primers; DNA Transposable Elements; Drug Resis | 2004 |
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Chronic Disease; Cohort Studies; Drug Resistance | 2004 |
Synthesis and anti-HIV activity of 4'-cyano-2',3'-didehydro-3'-deoxythymidine.
Topics: Animals; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Stavudine; Thymidine | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resis | 2004 |
Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
Topics: Adenine; Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organo | 2004 |
Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine Kinase; Fema | 2005 |
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.
Topics: Amino Acid Substitution; Clone Cells; Genotype; HIV; HIV Infections; Humans; Mutation; Thymidine | 2005 |
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Topics: Adenosine Triphosphate; Anti-HIV Agents; Base Sequence; Didanosine; DNA Primers; Drug Resistance, Vi | 2005 |
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy.
Topics: Adenine; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; H | 2005 |
HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Genes, pol; Government Programs; Health Surveys; HIV | 2005 |
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2005 |
[Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
Topics: Anti-HIV Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; HIV Infections; HIV Reverse Tra | 2005 |
Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA Mutational Analysis; DNA, Viral; Drug Re | 2006 |
Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1 | 2006 |
Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations.
Topics: Didanosine; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Nucleosides; Prospective St | 2006 |
Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; | 2006 |
Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Brazil; Chronic Disease; Drug Resistanc | 2006 |
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance; Endp | 2006 |
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideox | 2007 |
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Topics: Adenine; DNA Repair; Drug Resistance, Multiple, Viral; Genetic Engineering; HIV Infections; HIV Reve | 2007 |
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Fo | 2007 |
The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
Topics: Africa, Southern; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Vira | 2007 |
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients.
Topics: Europe; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Polymorphism, Single Nuc | 2007 |
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcrip | 2007 |
HIV-1-infected and/or immune-activated macrophage-secreted TNF-alpha affects human fetal cortical neural progenitor cell proliferation and differentiation.
Topics: Analysis of Variance; Animals; Cell Cycle; Cell Differentiation; Cell Proliferation; Cells, Cultured | 2008 |
Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues.
Topics: Adipose Tissue; Anti-HIV Agents; Biomarkers; Cell Proliferation; Cells, Cultured; Cellular Senescenc | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideox | 2008 |
Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; CD3 Complex; CD4-Positive T-Lymphocytes; CD8- | 1996 |
Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
Topics: Animals; Antiviral Agents; Drug Resistance; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans | 1995 |
Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase.
Topics: Cell Line; HIV Infections; HIV-1; Humans; Kinetics; Leukocytes, Mononuclear; Phosphorylation; T-Lymp | 1996 |
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Topics: Anti-HIV Agents; Base Sequence; DNA Primers; Drug Resistance, Microbial; Genes, Viral; Genetic Varia | 2000 |
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Arteriosclerosis; Benzoxazines; Cholesterol; Cyclopropanes; Drug Th | 2000 |
Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; H | 2001 |
Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Apoptosis Regulatory Proteins; Arabido | 2001 |
S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs.
Topics: Anti-HIV Agents; Antiviral Agents; Cell Division; Cell Line; Cytarabine; Deoxycytidine; Deoxycytidin | 2002 |
Inhibition of human immunodeficiency virus type 1 activity in vitro by a new self-stabilized oligonucleotide with guanosine-thymidine quadruplex motifs.
Topics: Giant Cells; Guanosine; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear | 2002 |
Differentiating agents facilitate infection of myeloid leukemia cell lines by monocytotropic HIV-1 strains.
Topics: Bucladesine; Calcitriol; CD4 Antigens; Cell Differentiation; Cell Line; Dimethyl Sulfoxide; DNA, Vir | 1990 |